Neurology targets GenWay Biotech is expanding capabilities in neurology-focused research through Aviva’s new anti-progranulin monoclonal antibody clones, presenting a cross-sell opportunity for neurology researchers and DIM-based projects needing high specificity antibodies and diagnostic tools.

Protein on Demand Aviva has a semi-custom recombinant protein portfolio and on-demand protein offerings, enabling tailored reagent solutions for customers with unique assay or preclinical study needs, a strong upsell path for GenWay Biotech clients.

ECL Western Growth The AvivaBlot line of ECL reagents for western blot provides a complementary product category that can drive bundle deals with existing antibody and immunoassay kit customers seeking streamlined workflows.

Integrated Martech GenWay’s tech stack includes HubSpot, SendGrid, Klaviyo and analytics tools, suggesting readiness for targeted campaigns to life-science researchers and labs, with opportunities to cross-sell new clones, protein on demand offerings, and diagnostic reagents.

Mid-market focus With 11-50 employees and revenue in the 10M–25M range, GenWay and its parent company target mid-market research labs, presenting a sales lane for standardized bundles, as well as semi-custom protein and antibody solutions tailored to mid-sized biotech accounts.